Evidence map›Paper›PMID 41907293›Full record

ArticleFrontiers in medicine2026

Diagnostic accuracy of

Luca Urso, Francesco Feletti, Federica Lancia, Francesca Canella, Corrado Cittanti, Ilham Badrane, Sara Adamantiadis, Licia Uccelli, Antonella Iudicello, Alberto Nieri and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Luca UrsoDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Francesco FelettiDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Federica LanciaOncology Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Francesca CanellaNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Corrado CittantiDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Ilham BadraneDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Sara AdamantiadisDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Licia UccelliDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Antonella IudicelloNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Alberto NieriNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Matteo CaraccioloNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Ilaria RambaldiNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.
Riccardo BisiUnità Operativa Radiologia Universitaria, Azienda Ospedaliero-Universitaria "S. Anna", Ferrara, Italy.
Luigi MancoMedical Physics Unit, University Hospital of Ferrara, Ferrara, Italy.
Ilaria BagniAnatomic Pathology Unit, University Hospital of Ferrara, Ferrara, Italy.
Massimo GuidoboniDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Luana CalabròDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Carmelo IppolitoUrology Unit, Surgical Department, University Hospital of Ferrara, Ferrara, Italy.
Melchiore GigantiDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Mirco BartolomeiNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferrara, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Muscle-invasive bladder cancer (MIBC) is associated with poor prognosis. Current staging relies on CT and MRI, but both show limited sensitivity for nodal and distant metastases. [ Methods and analysis: MIBC-PET is a prospective, monocentric, no-profit study with paired imaging comparison enrolling 60 patients with newly diagnosed, histologically confirmed high-grade MIBC. All patients undergo baseline staging with [ Ethics and dissemination: The study complies with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was approved by the local ethical committee (CE-AVEC 109-2024-Oss-AOUFe - P.I. Dr. Luca Urso, MD). Results will inform the integration of [ Trial registration: ClinicalTrials.gov, identifier: not yet assigned. Local trial registration code: CE-AVEC 109-2024-Oss-AOUFe.

Indexed as

18F-FDGartificial intelligencediagnostic accuracyFDG PETmuscle-invasive bladder cancerneoadjuvant chemotherapyPET/CTradiomics

Identifiers

PMID41907293
PMCPMC13017280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.